IBRX FY 2022 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$240,000-74.3% YoY

Gross Profit

$240,000100.0% margin

Operating Income

-$351M-146374.2% margin

Net Income

-$417M-173569.6% margin

EPS (Diluted)

$-1.04

Cash Flow

Operating Cash Flow

-$338M

Free Cash Flow

-$416M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$362M

Total Liabilities

$812M

Stockholders' Equity

-$447M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$240,000	$934,000	-74.3%
Gross Profit	$240,000	$934,000	-74.3%
Operating Income	-$351M	-$330M	-6.4%
Net Income	-$417M	-$347M	-20.1%